Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer

Theoretical Biology and Medical Modelling

Volumn 2, Issue , 2005, Pages

  Espinoza Fonseca, L Michel ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; UNCLASSIFIED DRUG; FURAN DERIVATIVE; LIGAND; MDM2 PROTEIN, HUMAN; NSC 652287;

ARTICLE; CANCER; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; PROTEIN DOMAIN; TRANSACTIVATION; APOPTOSIS; CHEMISTRY; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN CONFORMATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; HUMANS; LIGANDS; NEOPLASMS; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 26244440782     PISSN: 17424682     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-2-38     Document Type: Article

References (27)

1. Levine AJ: P53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
2. Wu L, Levine AJ: Differential regulation of the p21/WAF-1 and MDM2 genes after high-dose UV radiation: p53-dependent and p53-independent regulation of the MDM2 gene. Mol Med 1997, 3:441-451.
3. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2001, 2:594-604.
4. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
5. Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acid Res 1998, 26:3453-3459.
6. Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003, 3:102-109.
7. Chene P: Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res 2004, 2:20-28.
8. Chene P: Inhibition of the p53-HDM2 interaction with low molecular weight compounds. Cell Cycle 2004, 3:460-461.
9. Klein C, Vassilev LT: Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004, 91:1415-1319.
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
11. Parks DJ, Lafrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, Maguire D, Grasberger BL, Lu T: 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg Med Chem Lett 2005, 15:765-770.
12. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF: Discovery and co-crystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005, 48:909-912.
13. Raboisson P, Marugan JJ, Schubert C, Koblish HK, Lu T, Zhao S, Player MR, Maroney AC, Reed RL, Huebert ND, Lattanze J, Parks DJ, Cummings MD: Structure based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. Bioorg Med Chem Lett 2005, 15:1857-1861.
14. Hardcastle IS, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Kallblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J: Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction. Bioorg Med Chem Lett 2005, 15:1515-1520.
15. Kritzer JA, Hodsdon ME, Schepartz A: Solution structure of a β-peptide ligand for HDM2. J Am Chem Soc 2005, 5127:4118-4119.
16. Zhong H, Carlson HA: Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 2005, 58:222-234.
17. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004, 10:1321-1328.
18. Espinoza-Fonseca LM: The benefits of multi-target approach in drug design and discovery. Bioorg Med Chem 2005 in press.
19. Hetenyi C, van der Spoel D: Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 2002, 11:1729-1737.
20. Schon O, Friedler A, Freund S, Fersht AR: Binding of p53-derived ligands to MDM2 induces a variety of long-range conformational changes. J Mol Biol 2004, 336:197-202.
21. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-53.
22. Burch LR, Midgley CA, Currie RA, Lane DP, Hupp TR: Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Lett 2000, 472:93-98.
23. Van Regenmortel MH: Molecular recognition in the post-reductionistera. J Mol Recognit 1999, 12:1-2.
24. Stephenson VC, Heyding RA, Weaver DF: The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett 2005, 579:1338-1342.
25. Kale L, Skeel R, Bhandarkar M, Brunner R, Gursoy A, Krawetz N, Phillips J, Shinozaki A, Varadarajan K, Schulten K: NAMD2: Greater scalability for parallel molecular dynamics. J Comput Phys 1999, 151:283.
26. Gasteiger J, Marsili M: Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron 1980, 36:3219-3228.
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: Automated docking using Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19:1639-1662.